ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ITEK Inotek Pharmaceuticals Corp. (delisted)

3.04
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Inotek Pharmaceuticals Corp. (delisted) NASDAQ:ITEK NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.04 3.01 3.10 0 01:00:00

URGENT: Monteverde & Associates PC Invites Inotek Pharmaceuticals Corporation Shareholders with Losses To Contact The Firm Im...

25/02/2017 1:22am

PR Newswire (US)


INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more INOTEK PHARMACEUTICALS CORP Charts.

NEW YORK, Feb. 24, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, announces that a class action lawsuit has been filed in the U.S. District of Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ITEK)("Inotek" or the "Company") on behalf of purchasers of the Company's securities between July 23, 2015 and December 30, 2016, inclusive (the "Class Period"). 

The lawsuit is based on Inotek making false and/or misleading statements regarding the efficacy of its lead drug candidate for glaucoma and the only product it is currently developing in its pipeline, trabodenoson; and its attendant capacity to receive New Drug Approval by the U.S. Food and Drug Administration. Specifically, the lawsuit alleges that Inotek made positive statements about trabodenoson despite knowledge that the MATrX-1 phase 3 clinical trial would fail to meet its primary endpoint. When this information was revealed to the public, the value of Inotek stock dropped, causing losses to its shareholders.

Mr. Monteverde would like to personally discuss with you how to potentially recover your monetary losses, if incurred during the Class Period.

If you wish to serve as lead plaintiff, you must move the Court no later than March 7, 2017.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. 

Click here for more information: http://monteverdelaw.com/securities/It is free and there is no cost or obligation to you.

Monteverde & Associates PC is a boutique class action securities and consumer litigation law firm committed that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.  Monteverde & Associates PC lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. 59th Floor
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com 
Tel: (212) 971-1341

Attorney Advertising. (C) 2017 Monteverde & Associates PC.  Prior results do not guarantee a similar outcome with respect to any future matter. 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/urgent-monteverde--associates-pc-invites-inotek-pharmaceuticals-corporation-shareholders-with-losses-to-contact-the-firm-immediately---itek-300413544.html

SOURCE Monteverde & Associates PC

Copyright 2017 PR Newswire

1 Year INOTEK PHARMACEUTICALS CORP Chart

1 Year INOTEK PHARMACEUTICALS CORP Chart

1 Month INOTEK PHARMACEUTICALS CORP Chart

1 Month INOTEK PHARMACEUTICALS CORP Chart

Your Recent History

Delayed Upgrade Clock